Danazol increases the anticoagulant effect of warfarin

M. L. Meeks, K. W. Mahaffey, Michael Katz

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBJECTIVE: To report two cases demonstrating an interaction between danazol and warfarin, resulting in the potentiation of warfarin's effect and bleeding complications. DATA SOURCES: Case reports, review articles, and studies identified by MEDLINE. STUDY SELECTION: All published English- language reports involving danazol and warfarin interactions were reviewed. DATA SYNTHESIS: Danazol, a synthetic testosterone derivative, is used in the treatment of endometriosis, fibrocystic breast disease, menorrhagia protein C deficiency, and hemophilia. We describe two cases including an interaction between danazol and warfarin, resulting in bleeding complications. There are at least two other reported cases of this interaction. This interaction may be attributable to several mechanisms. Danazol may inhibit the metabolism of warfarin and/or it may have a direct effect on the coagulation and fibrinolytic systems. CONCLUSIONS: Based on this report and other published cases, clinicians must be aware that danazol may increase the anticoagulant effect of warfarin. Patients receiving warfarin who are prescribed danazol must be monitored closely to prevent excessive anticoagulation and subsequent bleeding. Studies are needed to determine the frequency of this interaction and its underlying mechanisms.

Original languageEnglish (US)
Pages (from-to)641-642
Number of pages2
JournalAnnals of Pharmacotherapy
Volume26
Issue number5
StatePublished - 1992

Fingerprint

Danazol
Warfarin
Anticoagulants
Hemorrhage
Fibrocystic Breast Disease
Protein C Deficiency
Menorrhagia
Hemophilia A
Endometriosis
MEDLINE
Testosterone
Language

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Danazol increases the anticoagulant effect of warfarin. / Meeks, M. L.; Mahaffey, K. W.; Katz, Michael.

In: Annals of Pharmacotherapy, Vol. 26, No. 5, 1992, p. 641-642.

Research output: Contribution to journalArticle

Meeks, ML, Mahaffey, KW & Katz, M 1992, 'Danazol increases the anticoagulant effect of warfarin', Annals of Pharmacotherapy, vol. 26, no. 5, pp. 641-642.
Meeks, M. L. ; Mahaffey, K. W. ; Katz, Michael. / Danazol increases the anticoagulant effect of warfarin. In: Annals of Pharmacotherapy. 1992 ; Vol. 26, No. 5. pp. 641-642.
@article{5e0bf3c9ab6945c78a3a273683f682bc,
title = "Danazol increases the anticoagulant effect of warfarin",
abstract = "OBJECTIVE: To report two cases demonstrating an interaction between danazol and warfarin, resulting in the potentiation of warfarin's effect and bleeding complications. DATA SOURCES: Case reports, review articles, and studies identified by MEDLINE. STUDY SELECTION: All published English- language reports involving danazol and warfarin interactions were reviewed. DATA SYNTHESIS: Danazol, a synthetic testosterone derivative, is used in the treatment of endometriosis, fibrocystic breast disease, menorrhagia protein C deficiency, and hemophilia. We describe two cases including an interaction between danazol and warfarin, resulting in bleeding complications. There are at least two other reported cases of this interaction. This interaction may be attributable to several mechanisms. Danazol may inhibit the metabolism of warfarin and/or it may have a direct effect on the coagulation and fibrinolytic systems. CONCLUSIONS: Based on this report and other published cases, clinicians must be aware that danazol may increase the anticoagulant effect of warfarin. Patients receiving warfarin who are prescribed danazol must be monitored closely to prevent excessive anticoagulation and subsequent bleeding. Studies are needed to determine the frequency of this interaction and its underlying mechanisms.",
author = "Meeks, {M. L.} and Mahaffey, {K. W.} and Michael Katz",
year = "1992",
language = "English (US)",
volume = "26",
pages = "641--642",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "5",

}

TY - JOUR

T1 - Danazol increases the anticoagulant effect of warfarin

AU - Meeks, M. L.

AU - Mahaffey, K. W.

AU - Katz, Michael

PY - 1992

Y1 - 1992

N2 - OBJECTIVE: To report two cases demonstrating an interaction between danazol and warfarin, resulting in the potentiation of warfarin's effect and bleeding complications. DATA SOURCES: Case reports, review articles, and studies identified by MEDLINE. STUDY SELECTION: All published English- language reports involving danazol and warfarin interactions were reviewed. DATA SYNTHESIS: Danazol, a synthetic testosterone derivative, is used in the treatment of endometriosis, fibrocystic breast disease, menorrhagia protein C deficiency, and hemophilia. We describe two cases including an interaction between danazol and warfarin, resulting in bleeding complications. There are at least two other reported cases of this interaction. This interaction may be attributable to several mechanisms. Danazol may inhibit the metabolism of warfarin and/or it may have a direct effect on the coagulation and fibrinolytic systems. CONCLUSIONS: Based on this report and other published cases, clinicians must be aware that danazol may increase the anticoagulant effect of warfarin. Patients receiving warfarin who are prescribed danazol must be monitored closely to prevent excessive anticoagulation and subsequent bleeding. Studies are needed to determine the frequency of this interaction and its underlying mechanisms.

AB - OBJECTIVE: To report two cases demonstrating an interaction between danazol and warfarin, resulting in the potentiation of warfarin's effect and bleeding complications. DATA SOURCES: Case reports, review articles, and studies identified by MEDLINE. STUDY SELECTION: All published English- language reports involving danazol and warfarin interactions were reviewed. DATA SYNTHESIS: Danazol, a synthetic testosterone derivative, is used in the treatment of endometriosis, fibrocystic breast disease, menorrhagia protein C deficiency, and hemophilia. We describe two cases including an interaction between danazol and warfarin, resulting in bleeding complications. There are at least two other reported cases of this interaction. This interaction may be attributable to several mechanisms. Danazol may inhibit the metabolism of warfarin and/or it may have a direct effect on the coagulation and fibrinolytic systems. CONCLUSIONS: Based on this report and other published cases, clinicians must be aware that danazol may increase the anticoagulant effect of warfarin. Patients receiving warfarin who are prescribed danazol must be monitored closely to prevent excessive anticoagulation and subsequent bleeding. Studies are needed to determine the frequency of this interaction and its underlying mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0026556184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026556184&partnerID=8YFLogxK

M3 - Article

C2 - 1591422

AN - SCOPUS:0026556184

VL - 26

SP - 641

EP - 642

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 5

ER -